CLIA NOW AVAILABLE! BOOST CLINICAL LAB EFFICIENCY WITH THE THUNDERBOLT® EIA+CLIA AUTOMATION PLATFORM

Enhanced features announced at AACC 2012 provides superior flexibility in a dual function analyzer.

July 17, 2012, Los Angeles, CA – Gold Standard Diagnostics (GSD) today announced the addition of fully-automated Chemiluminescence Immunoassay (CLIA) processing capability to the powerful ThunderBolt® Automation Platform. With the ability to simultaneously automate CLIA alongside EIA, laboratories of any size can now achieve even more dramatic increases in throughput, flexibility and cost savings. The CLIA enhancement firmly establishes the ThunderBolt® as the most full-featured, compact analyzer on the market. See the ThunderBolt® in action at the 2012 AACC Lab Expo, booth #2222 in the Los Angeles Convention Center from July 17th-19th.

Powerful, Flexible, Innovative and Compact…

Through a host of patent-pending features, the ThunderBolt® delivers exceptional power and flexibility in a small size. The dual function analyzer provides complete, walk-away automation of 192 patient samples in only a 2’ by 2’ space. Completely open architecture allows any EIA or CLIA protocol to be programmed, and up to eight different protocols to run in a single batch. Intuitive and robust software further enriches the ThunderBolt®, making it the total laboratory automation solution.

More information: http://www.gsdx.us/thunderbolt or AACC 2012, Booth #2222